Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. - Brudno JN; Natrakul DA; Karrs J; Patel N; Maass-Moreno R; Ahlman MA; Mikkilineni L; Mann J; Stroncek DF; Highfill SL; Fromm GC; Patel R; et al. (Blood advances, 2024)